Ask AI
ASH 2025 Nonmalignant Hematologic Disorders

CE / CME

Emerging Data and Clinical Implications in Nonmalignant Hematologic Disorders: ASH 2025 Highlights

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: February 20, 2026

Expiration: August 19, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Cuker A, Stauch T, Cooper N, et al. Ianalumab plus eltrombopag in immune thrombocytopenia. N Engl J Med. 2025;[Epub ahead of print].
  2. Al-Samkari H, Cuker A, Zaja F, et al. Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment. Presented at: 2025 American Society of Hematology Annual Meeting. December 6-9, 2025. Abstract LBA2.
  3. Choi P, Bradbury C, Gonzalez-Lopez TJ, et al. Secondary analysis results from VAYHIT3, a phase 2 study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy. Presented at: 2025 American Society of Hematology Annual Meeting. December 6-9, 2025. Abstract 844.
  4. Palchuk, Matvey B, London JW, Perez-Rey D, et al. A global federated real-world data and analytics platform for research. JAMA Open. 2023;6:ooad035.
  5. ‌Sohail H, Wilson L, Collins J, et al. Deciphering the dilemma: Intravenous (IV) iron use in iron deficiency anemia during acute infections. Presented at: 2025 American Society of Hematology Annual Meeting. December 6-9, 2025. Abstract 5.
  6. Wheeler A, Kshirsagar S, Giermasz A, et al. Subcutaneous, every-four-week maintenance dosing of a novel protein S antibody is well-tolerated and substantially reduces bleeding rates: Results from A phase 1/2 multidose study of VGA039 in patients with von Willebrand disease. Presented at: 2025 American Society of Hematology Annual Meeting. December 6-9, 2025. Abstract 308.
  7. Leaf RK, Mones JV, Shenoy T, et al. Immune thrombocytopenia in patients treated with immune checkpoint inhibitors. Presented at: 2025 American Society of Hematology Annual Meeting. December 6-9, 2025. Abstract 841.